Eisinger Lab

Publications

YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, Ciotti GE, Lee AC, Marino GE, Shah J, Niedzwicki D, Weber K, Park PMC, Alam MZ, Grazioli A, Haldar M, Xu M, Perry JA, Qi J, Eisinger-Mathason TSK.   
Cancer Res. 2018 May 15;78(10):2705-2720. doi: 10.1158/0008-5472.CAN-17-4052. Epub 2018 Feb 28.

Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, Eisinger-Mathason TSK, Brem H, Tyler B, Skuli N.
Oncogene. 2017 May 25;36(21):3037-3047. doi: 10.1038/onc.2016.457. Epub 2016 Dec 12.

The Bad, the Good and eIF3e/INT6.
Sesen J, Casaos J, Scotland SJ, Seva C, Eisinger-Mathason TS, Skuli N.
Front Biosci (Landmark Ed). 2017 Jan 1;22:1-20. Review.

Intratumoral oxygen gradients mediate sarcoma cell invasion.
Lewis DM, Park KM, Tang V, Xu Y, Pak K, Eisinger-Mathason TS, Simon MC, Gerecht, S.

Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth.
Nakazawa MS, Eisinger-Mathason TS, Sadri N, Ochocki JD, Gade TP, Amin RK, Simon MC.

Targeting the Hippo pathway: Clinical implications and therapeutics.
Ye S, Eisinger-Mathason TS.

Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis.
Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S, Simon MC.

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.
Yoon C, Lee HJ, Park DJ, Lee YJ, Tap WD, Eisinger-Mathason TS, Hart CP, Choy E, Simon MC, Yoon SS.

Feedback circuitry between miR-218 repression and RTK activation in glioblastoma.
Mathew LK, Huangyang P, Mucaj V, Lee SS, Skuli N, Eisinger-Mathason TS, Biju K, Li B, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Simon MC.

The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability.
Krock BL, Eisinger-Mathason TS, Giannoukos DN, Shay JE, Gohil M, Lee DS, Nakazawa MS, Sesen J, Skuli N, Simon MC.

Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature.
Lee HJ, Yoon C, Park do J, Kim YJ, Schmidt B, Lee YJ, Tap WD, Eisinger-Mathason TS, Choy E, Kirsch DG, Simon MC, Yoon SS.

MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma.
Mucaj V, Lee SS, Skuli N, Giannoukos DN, Qiu B, Eisinger-Mathason TS, Nakazawa MS, Shay JE, Gopal PP, Venneti S, Lal P, Minn AJ, Simon MC, Mathew LK.

Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer.
Shay JE, Imtiyaz HZ, Sivanand S, Durham AC, Skuli N, Hsu S, Mucaj V, Eisinger-Mathason TS, Krock BL, Giannoukos DN, Simon MC.

Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis.
Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JE, Stangenberg L, Sadri N, Puré E, Yoon SS, Kirsch DG, Simon MC.

Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.
Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC, Yoon SS.

Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival.
Eisinger-Mathason TS, Andrade J, Groehler AL, Clark DE, Muratore-Schroeder TL, Pasic L, Smith JA, Shabanowitz J, Hunt DF, Macara IG, Lannigan DA.


© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.